康乃德生物医药:Rademikibart在哮喘患者中展现良好耐受性与低不良事件发生率

美股速递
Yesterday

在哮喘治疗领域,康乃德生物医药传来令人振奋的消息——其研发的药物Rademikibart展现出卓越的安全性特征。这一候选药物在患者群体中表现出良好的耐受性,同时不良反应的发生率维持在较低水平,为饱受哮喘困扰的患者带来了新的希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10